Company: PCRX
Filing Date: 2025-03-14
Form Type: DEFA14A
Source: 0001104659-25-024033
Chunk: 1

Company: Pacira BioSciences, Inc.
Filing Date: 2025-03-14
Form: DEFA14A
Chunk 1
---
 Sustainability Committee of the Pacira Board will evaluate and consider DOMA’s proposed candidates, as it does with all director candidates.”

The Board will present its formal recommendation
regarding director nominees in the Company’s definitive proxy statement and other materials, to be filed with the Securities and
Exchange Commission and mailed to all shareholders eligible to vote at the 2025 Annual Meeting of Stockholders.

The date of the Annual Meeting has not yet
been announced and shareholders are not required to take any action at this time.

Evercore is serving as financial advisor and
Wachtell, Lipton, Rosen & Katz is serving as legal advisor to the Company.

About Pacira

Pacira delivers innovative, non-opioid pain
therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine
liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene
brachial plexus nerve block for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release
injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº,
a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature
to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the
potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Forward-Looking Statements

Any statements in this document about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2025 Annual Meeting, ‘5x30’, Pacira’s growth and business strategy; Pacira’s future outlook, Pacira’s intellectual property and patent terms